Detailed Coverage

Shivalik Rasayan Board Approves ₹33 Crore Preferential Issue

Shivalik Rasayan Limited will raise up to ₹33 crore through a preferential issuance of equity shares and fully convertible warrants.

Reader Takeaway: Capital infusion for growth, but watch for potential dilution from warrants.

What just happened

Shivalik Rasayan's board has approved a plan to raise capital via a preferential issue. This includes issuing 3,72,000 equity shares at ₹250 each, totaling ₹9.30 crore. Additionally, 9,48,000 fully convertible warrants will be issued at ₹250 each, amounting to ₹23.70 crore. These warrants can be converted into equity shares within 18 months of allotment.

Why this matters

This capital infusion of ₹33 crore is intended to bolster the company's financial position and support its future operational or strategic objectives. The issuance structure, combining immediate equity with convertible warrants, offers flexibility.

The backstory

Shivalik Rasayan operates in the pharmaceutical sector, focusing on the manufacturing of active pharmaceutical ingredients (APIs) and intermediates. This capital raise is a strategic move to fund growth initiatives.

What changes now

The issuance is subject to shareholder approval at an Extra-Ordinary General Meeting (EGM) scheduled for August 20, 2026, and regulatory clearances. A Preferential Issue Committee has been formed to oversee the process.

Risks to watch

Existing shareholders should be aware of potential equity dilution once the warrants are converted into shares. The company's ability to effectively deploy the raised capital for growth will be crucial.

Peer comparison

Pharmaceutical companies frequently tap capital markets for funding research, expansion, and working capital needs. The pricing and terms of Shivalik Rasayan's issue will be compared against similar recent issuances in the sector.

Context metrics (time-bound)

The warrants are convertible into equity within 18 months from their allotment date. The EGM to seek shareholder nod is scheduled for August 20, 2026.

What to track next

Investors should monitor the outcome of the EGM, regulatory approvals, and the subsequent conversion of warrants. The company's utilization of funds and its impact on financial performance will be key indicators.